Compare Biogen Inc (BIIB) vs TeraWulf Inc (WULF) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

WULF trades at $20.89, down 4.92% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $661.42 million in 2025, with revenue of $168.46 million, but secured a significant 20-year, $19 billion AI infrastructure deal with Anthropic, driving positive analyst sentiment. Key support lies at $20, with resistance at $21.

The outlook hinges on execution of the Anthropic partnership, offering substantial growth potential, but high valuation ratios and persistent losses pose risks. Analyst consensus is strongly bullish with a $35.40 price target, though operational cash flow remains negative. Investors face volatility from execution delays and competitive pressures in AI infrastructure.